A personalized approach to sustainable weight management

Body weight is influenced by multiple factors, including appetite regulation, metabolic adaptation, genetics, age-related changes, and hormones. For some adults with obesity or overweight plus related health conditions, lifestyle measures alone may not produce the desired results. Certain FDA-approved GLP-1 receptor agonists have been shown in clinical trials to support weight reduction when used together with diet and physical activity under medical supervision. These medications are prescription-only and are not a substitute for lifestyle changes or a reflection of personal discipline. A licensed healthcare provider evaluates each individual’s medical history, current health status, and goals to determine whether any medication is appropriate.

Ozempic and Wegovy contain the active ingredient semaglutide and are FDA-approved products. Mounjaro and Zepbound contain the active ingredient tirzepatide and are also FDA-approved products. Each has undergone FDA review for safety, effectiveness, and quality for specific indications. Compounded versions of semaglutide or tirzepatide (sometimes prepared with additional ingredients such as glycine or B12) are not FDA-approved. Compounded drugs are prepared by a state-licensed pharmacy for an individual patient pursuant to a prescription and are not reviewed by the FDA for safety, effectiveness, or quality before they are marketed. They are not the same as, and are not interchangeable with, the FDA-approved branded products. A licensed clinician determines whether any form of these medications is medically appropriate for a specific patient.

Responses vary widely. Some people report changes in appetite or cravings within the first several weeks of treatment with an FDA-approved GLP-1 receptor agonist, while visible changes in weight or body composition typically occur more gradually over months and depend on dose titration, adherence, lifestyle factors, and individual biology. These medications are generally intended for longer-term use under ongoing medical supervision rather than short courses. A healthcare provider monitors progress and can adjust the treatment plan as needed. Results are not guaranteed and differ from person to person.

Semaglutide acts primarily on the GLP-1 receptor. Tirzepatide is a dual agonist that acts on both the GLP-1 and GIP receptors. Both are available as once-weekly injectable formulations in their FDA-approved forms. The choice of medication (if any), starting dose, and titration schedule is a clinical decision made by a licensed healthcare provider after reviewing the individual’s medical history, laboratory results, treatment goals, potential risks, and other relevant factors. There is no universal “starting” or “step-up” sequence that applies to every person.

Access to any GLP-1 receptor agonist requires evaluation by a licensed healthcare provider. This usually involves a medical intake, review of health history, and a clinical consultation (which may occur via telehealth where permitted by applicable state and federal rules). You can connect with a provider here. If the clinician determines that a prescription is appropriate, it is sent to a pharmacy. Compounded versions, when used, are prepared for a specific patient and are not FDA-approved finished products. Not every individual is a candidate for these medications. A clinician will discuss potential benefits, risks, alternatives, and monitoring requirements before any prescription is issued.